Announced
Completed
Financials
Sources
Tags
Private Equity
Cross Border
Completed
Biotechnology
biopharmaceuticals
United States
Private
Venture Capital
Friendly
Acquisition
Minority
Synopsis
Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners led a $112 Series B funding round in Neumora Therapeutics, a clinical-stage biotechnology company pioneering precision medicines for brain diseases. “This Series B financing reflects Neumora’s continued progress in building a best-in-class neuroscience company, including assembling a world-class team, scaling up an industry-leading data science and translational neuroscience platform, and advancing a broad and growing pipeline of seven development programs, including our internal discovery efforts and business development activities. This considerable amount of progress in such a short period of time reflects our urgency to address the relative lack of progress and innovation in neuroscience with our data-driven, precision medicine approach," Paul L. Berns, Neumora Co-Founder, Chairman and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.